Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | LCAT | P04180 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001062 | 0.84 | SMO (0.38) | PARP1SLC6A9CHRM2ALDH1A1 | |
| SCHEMBL24967959 | 0.83 | SMN1; SMN2 (0.46) | PARP1SLC6A9ALDH1A1 | |
| SCHEMBL3708309 | 0.77 | HTR3A (0.35) | — | |
| SCHEMBL16429791 | 0.77 | HTR3A (0.35) | — | |
| SCHEMBL3919810 | 0.77 | ADRB1 (0.50) | PARP1LCATALDH1A1 | |
| SCHEMBL15173793 | 0.77 | HTR3A (0.35) | CHRM2 | |
| SCHEMBL2733659 | 0.76 | MAPT (0.59) | ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL31381916 | 0.75 | ADRB1 (0.49) | PARP1LCATALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL25313044 | 0.75 | ADRB1 (0.49) | PARP1LCATALDH1A1MAPT | |
| SCHEMBL26194493 | 0.75 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | PARP1 2/4885SLC6A9 4878/4885NR1H2 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.